21 May 2013
Keywords: Bayer, AC Immune, Research, Licensing, florbetaben, Alzheimer's
Article | 12 October 2009
German drug major Bayer Schering Pharma will provide its development candidate florbetaben, a so called PET (positron emission tomography) tracer, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.